← Leaderboards
Matthew L Warman
Case Western Reserve University
$11,497,811
Attributed
$15,565,151
Total exposure
17
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,565,151 · 17
By mechanism
R01$12,368,359 · 5
R21$2,627,736 · 6
R56$471,032 · 2
M01$53,102 · 1
R13$25,000 · 1
P41$19,922 · 2
Top collaborators
- Alexander G Robling9 shared
- Gregory D. Jay5 shared
- April Marie Craft3 shared
- Kyle C Kurek1 shared
- Larry J. Suva1 shared
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationAffectGenesPhenotypePreventResearch PersonnelGeneticPropertyCellsAllelesMouse ModelSkeletalAnimalsProteinsMediatingMutantBoneResponseBone MassResourcesAnimal ModelPathway InteractionsInterestTissues
Grant awards (50)
Lrp5 and Lrp6 signaling in bone mechanotransduction and metabolism$315,456
R01 · FY2025 · AR
In vivo assessment of variants of uncertain significance in the intellectual disability gene ANKRD17$221,250
R21 · FY2025 · HD · contact PI
Lrp5 and Lrp6 signaling in bone mechanotransduction and metabolism$727,957
R01 · FY2024 · AR
Skeletal and non-skeletal roles for osteocalcin$377,718
R01 · FY2024 · AR · contact PI
In vivo assessment of variants of uncertain significance in the intellectual disability gene ANKRD17$265,500
R21 · FY2024 · HD · contact PI
Conditional mouse models with dominant negative Osteogenesis Imperfecta$188,859
R21 · FY2024 · AR · contact PI
WISP3 and Progressive Pseudorheumatoid Arthropathy of Childhood$122,284
R56 · FY2024 · AR
Skeletal and non-skeletal roles for osteocalcin$405,718
R01 · FY2023 · AR · contact PI
Lrp5 and Lrp6 signaling in bone mechanotransduction and metabolism$348,748
R56 · FY2023 · AR
Conditional mouse models with dominant negative Osteogenesis Imperfecta$233,640
R21 · FY2023 · AR · contact PI
Skeletal and non-skeletal roles for osteocalcin$398,052
R01 · FY2022 · AR · contact PI
Neurobehavioral phenotypes of mouse models of Osteogenesis Imperfecta$231,304
R21 · FY2022 · AR · contact PI
Lrp4 signaling in bone metabolism and mechanotransduction$607,734
R01 · FY2021 · AR
Neurobehavioral phenotypes of mouse models of Osteogenesis Imperfecta$194,700
R21 · FY2021 · AR · contact PI
Lrp4 signaling in bone metabolism and mechanotransduction$634,362
R01 · FY2020 · AR
Progressive Pseudorheumatoid Arthropathy of Childhood$194,700
R21 · FY2020 · AR
Lrp4 signaling in bone metabolism and mechanotransduction$656,868
R01 · FY2019 · AR
Progressive Pseudorheumatoid Arthropathy of Childhood$233,640
R21 · FY2019 · AR
Lrp4 signaling in bone metabolism and mechanotransduction$97,963
R01 · FY2019 · AR
Lrp4 signaling in bone metabolism and mechanotransduction$663,798
R01 · FY2018 · AR
Non-heritable genetic diseases of the skeletal system: Pathogenesis and Treatment$389,400
R01 · FY2018 · AR · contact PI
Lrp4 signaling in bone metabolism and mechanotransduction$650,545
R01 · FY2017 · AR
Non-heritable genetic diseases of the skeletal system: Pathogenesis and Treatment$389,400
R01 · FY2017 · AR · contact PI
Non-heritable genetic diseases of the skeletal system: Pathogenesis and Treatment$389,400
R01 · FY2016 · AR · contact PI
The Efficacy of combination therapy in Osteogenesis Imperfecta$155,760
R21 · FY2016 · AR · contact PI
Non-heritable genetic diseases of the skeletal system: Pathogenesis and Treatment$388,300
R01 · FY2015 · AR · contact PI
The Efficacy of combination therapy in Osteogenesis Imperfecta$271,810
R21 · FY2015 · AR · contact PI
Non-heritable genetic diseases of the skeletal system: Pathogenesis and Treatment$386,100
R01 · FY2014 · AR · contact PI
Mechanistic and Therapeutic Insights into Skeletal Biology Learned from the Study$25,000
R13 · FY2014 · AR · contact PI
Lubricin function in articulating joints$479,116
R01 · FY2012 · AR · contact PI
Does increasing bone mass also increase bone strength in mouse models of OI?$151,157
R21 · FY2012 · AR · contact PI
Lubricin function in articulating joints$479,520
R01 · FY2011 · AR · contact PI
Does increasing bone mass also increase bone strength in mouse models of OI?$285,416
R21 · FY2011 · AR · contact PI
Lubricin function in articulating joints$487,864
R01 · FY2010 · AR · contact PI
Lubricin function in articulating joints$482,449
R01 · FY2009 · AR · contact PI
Lubricin function in articulating joints$524,814
R01 · FY2008 · AR · contact PI
Lubricin Function in Articulating Joints$406,305
R01 · FY2007 · AR · contact PI
HIP JOINT REPLACEMENT FOR IDIOPATHIC OSTEOARTHRITIS AGGREGATES IN FAMILIES$5,145
P41 · FY2007 · RR · contact PI
Lubricin Function in Articulating Joints$408,525
R01 · FY2006 · AR · contact PI
HIP JOINT REPLACEMENT FOR IDIOPATHIC OSTEOARTHRITIS AGGREGATES IN FAMILIES$14,777
P41 · FY2006 · RR · contact PI
Lubricin Function in Articulating Joints$413,166
R01 · FY2005 · AR
PAMIDRONATE IN CHILDREN WITH MODERATE TO SEVERE OSTEOGENESIS IMPERFECTA$1,587
M01 · FY2005 · RR
Lubricin Function in Articulating Joints$403,365
R01 · FY2004 · AR
Pamidronate in children with moderate to severe osteogenesis imperfecta$32,316
M01 · FY2004 · RR
Lubricin Function in Articulating Joints$411,868
R01 · FY2003 · AR
PAMIDRONATE IN CHILDREN W/ MODERATE TO SEVERE OSTEOGENESIS IMPERFECTA$0
M01 · FY2002 · RR
GENETICS OF JOINT FAILURE$198,846
R01 · FY2001 · AR
PAMIDRONATE IN CHILDREN W/ MODERATE TO SEVERE OSTEOGENESIS IMPERFECTA$0
M01 · FY2001 · RR
GENETICS OF JOINT FAILURE$193,750
R01 · FY2000 · AR
PAMIDRONATE IN CHILDREN W/ MODERATE TO SEVERE OSTEOGENESIS IMPERFECTA$19,199
M01 · FY2000 · RR